Home LiteratureArticle Details
PMID: 12716700 Published · ppublish English Journal Article Review

Group B streptococcal conjugate vaccines.

Archives of disease in childhood ·Vol. 88 ·No. 5 ·2003-05-00 ·Pages 375-8

Baker CJ, Edwards MS

Abstract

Linkage of bacterial capsular polysaccharides to proteins to create conjugate vaccines has had a dramatic impact on the health of children. Although unconjugated polysaccharides are poorly immunogenic in infants and some older children and adults, their covalent coupling with proteins stimulates T cell dependent antigenic recognition that profoundly enhances immunogenicity. In the decade since the introduction and widespread use of Haemophilus influenzae type b polysaccharide conjugate vaccines in the United States, invasive H influenzae infections have become a rarity in childhood. Similarly, the conjugation of polysaccharides of Streptococcus pneumoniae to a derivative of diphtheria toxoid and the addition of pneumococcal conjugate vaccine to infant immunisation schedules carries with it promise for a similar decline in the incidence of invasive pneumococcal disease in paediatric patients.

MeSH Terms
Adult Antibodies, Bacterial/immunology Bacterial Capsules/immunology Child Clinical Trials as Topic Dose-Response Relationship, Immunologic Female Haemophilus Infections/prevention & control Haemophilus influenzae type b/immunology Humans Immunization/methods Infant Licensure Male Pneumococcal Vaccines Serotyping Streptococcal Infections/prevention & control Streptococcal Vaccines/immunology,therapeutic use Streptococcus agalactiae/immunology Streptococcus pneumoniae/immunology Tetanus Toxoid/immunology Vaccines, Conjugate/therapeutic use
Chemicals
Antibodies, Bacterial Pneumococcal Vaccines Streptococcal Vaccines Tetanus Toxoid Vaccines, Conjugate
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Baker C J
Section of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA.
Edwards M S
References (22)
22 references, click to expand
  1. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.
    N Engl J Med. 2000 Jan 6;342(1):15-20 PMID: 10620644
  2. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    J Infect Dis. 1999 Jan;179(1):142-50 PMID: 9841833
  3. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
    J Infect Dis. 2000 Oct;182(4):1129-38 PMID: 10979909
  4. Invasive group B streptococcal disease in Maryland nursing home residents.
    J Infect Dis. 2001 Apr 1;183(7):1138-42 PMID: 11237844
  5. Group B streptococcal disease in nonpregnant adults.
    Clin Infect Dis. 2001 Aug 15;33(4):556-61 PMID: 11462195
  6. Group B streptococcal disease: from trials and tribulations to triumph and trepidation.
    Clin Infect Dis. 2001 Sep 15;33(6):751-6 PMID: 11512078
  7. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.
    J Infect Dis. 2001 Oct 15;184(8):1022-8 PMID: 11574917
  8. Maternal immunization: the influence of liability issues on vaccine development.
    Vaccine. 2001 Oct 15;20 Suppl 1:S73-4 PMID: 11587817
  9. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
    Infect Immun. 2001 Nov;69(11):6696-701 PMID: 11598040
  10. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective.
    Antimicrob Agents Chemother. 2001 Dec;45(12):3623-4 PMID: 11709354
  11. The pneumococcus: carriage, disease and conjugate vaccines.
    J Med Microbiol. 2002 Feb;51(2):98-104 PMID: 11863272
  12. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.
    N Engl J Med. 1976 Apr 1;294(14):753-6 PMID: 768760
  13. Group B streptococcal vaccines.
    Rev Infect Dis. 1985 Jul-Aug;7(4):458-67 PMID: 3898306
  14. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus.
    N Engl J Med. 1988 Nov 3;319(18):1180-5 PMID: 3050524
  15. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
    J Clin Invest. 1990 Nov;86(5):1428-33 PMID: 2243123
  16. Progress towards the global elimination of neonatal tetanus.
    World Health Stat Q. 1992;45(2-3):248-56 PMID: 1462659
  17. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    J Clin Invest. 1996 Nov 15;98(10):2308-14 PMID: 8941648
  18. Group B streptococcus bacteremia in nonpregnant adults.
    Arch Intern Med. 1997 Jan 27;157(2):213-6 PMID: 9009979
  19. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program.
    J Infect Dis. 1998 Apr;177(4):998-1002 PMID: 9534974
  20. Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis.
    Antimicrob Agents Chemother. 1998 Jun;42(6):1517-9 PMID: 9624508
  21. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin.
    Obstet Gynecol. 1998 Aug;92(2):258-61 PMID: 9699763
  22. Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups.
    Clin Infect Dis. 2000 Feb;30(2):276-81 PMID: 10671328
Article Info
Journal
Archives of disease in childhood
Abbr.
Arch Dis Child
ISSN
1468-2044
Published
2003-05-00
Pages
375-8
Language
English
Region
England
NLM ID
0372434
PMCID
PMC1719562
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]